特色专场 生物制造青年论坛 8月20日，浙江·宁波 生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 SynBioCon 大会 | 生物制造青年论坛 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （ ...

Core Viewpoint - The article discusses the innovative approach of Ecopha Biotech, founded by Dr. Wilson Ling, to significantly reduce the cost of PHA (polyhydroxyalkanoates) production by utilizing non-food plant oils, specifically Pongamia oil, as a raw material, aiming to compete with traditional petroleum-based plastics [2][9][31]. Group 1: Industry Background - The biodegradable materials market, including PLA and PBAT, has faced challenges such as oversupply and performance limitations, leading to a decline in production rates [6][7]. - PHA stands out due to its advantages like "biomanufacturing," "marine biodegradability," and high thermal resistance (up to 100°C), with the global market expected to reach $367 million by 2030 [6][9]. - The current cost of PHA exceeds 40,000 yuan per ton, making it difficult to compete with petroleum-based plastics priced below 10,000 yuan per ton [7][9]. Group 2: Company Background - Ecopha Biotech was established in June 2025, with Dr. Wilson Ling returning to China after years of research and entrepreneurship abroad, driven by the desire to overcome the cost barriers of PHA production [9][19]. - The company aims to leverage a patented strain of bacteria and non-food oils to achieve a significant reduction in production costs [9][22]. Group 3: Raw Material Cost Reduction - The primary focus for cost reduction is on raw materials, which account for over 50% of PHA production costs. Traditional sugar-based routes have a conversion rate capped at 30%, leading to high costs [22][23]. - Dr. Ling's research determined that using plant oils, particularly Pongamia oil, could achieve a conversion rate of over 80%, significantly lowering production costs [22][31]. - Pongamia oil is non-food, cost-effective (half the price of palm oil), and has a high yield, making it suitable for sustainable production [25][30][31]. Group 4: Technological Advancements - Ecopha Biotech has completed laboratory and pilot-scale validations for using Pongamia oil and has designed a process package for a large-scale production line [32]. - The company plans to focus on medical products initially, targeting the Australian market, where there is a high demand for biodegradable medical supplies [33]. - The first production line in China is expected to replace 15,000 to 20,000 tons of petroleum-based plastics annually once operational [33]. Group 5: Future Outlook - Dr. Ling envisions that the real competition for PHA is not other bioplastics but the vast quantities of petroleum-based plastics that contribute to environmental pollution [34]. - The company aims to collaborate with domestic peers to promote the large-scale industrialization of PHA, potentially alleviating plastic pollution issues as production scales up [34].

SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （ ...

Project Overview - The project is named "Jinan Baijie High-Performance New Enzyme Preparation R&D and Industrialization Construction Project" [2] - The construction unit is Jinan Baijie Biological Engineering Co., Ltd., located in the Shanghe Chemical Industry Park, Jinan, covering an area of 70,067.81 m² (approximately 105.1 acres) [2] Investment and Construction Details - The total investment for the project is 775.49 million yuan, with phase one investment at 562.24 million yuan and phase two at 213.25 million yuan [3] - Environmental investment for phase one is 41.59 million yuan (7.39% of total investment), and for phase two is 6.21 million yuan (2.91% of total investment), all funded by the company [3] - The construction period for both phases is 21 months each [4] Production Capacity and Facilities - The project includes the construction of a fermentation workshop with a total of 12 fermentation tanks (6 in each phase), and two extraction and blending workshops [4] - The total production capacity for high-performance new enzyme preparations will be 45,000 tons per annum (t/a), with each phase contributing 22,500 t/a [4] Existing Product Situation - The northern fermentation workshop has been out of production for several years, while the southern workshop is operational [6] - The northern workshop has an annual production capacity of 1,500 tons for α-galactosidase, while the southern workshop has capacities of 5,200 t/a for liquid single enzyme products, 3,000 t/a for liquid proteases, and 8,000 t/a for liquid glucose oxidase and liquid fat enzymes, totaling 17,700 t/a for the entire plant [7] Company Background - Jinan Baijie Biological Engineering Co., Ltd. was formerly known as Jinan Nuoneng Biological Engineering Co., Ltd. and is a wholly-owned subsidiary of Kingsoft Bio-Technology (HK01548), established in 2009 [9] - The company specializes in the R&D, production, and sales of biological enzyme preparations, focusing on feed and industrial enzyme preparations, with core products including glucose oxidase, phytase, and compound enzymes [10]

Group 1 - The research team led by He Wei focused on developing new productive forces tailored to local conditions to promote the rapid rise of the central region during their visit to Henan [1][2] - He Wei emphasized the strategic importance of Henan as a major population, economic, and agricultural province, highlighting the need for the central region to accelerate its rise as part of a national strategy [2] - The team conducted field research at various institutions, including medical colleges and emergency rescue practice stations, to assess the implementation of Red Cross work and gather insights on local governance and development [1][2] Group 2 - The central government's strategy for the rise of the central region is a significant decision based on the overall modernization of the country, requiring adherence to key political principles and the implementation of relevant policies [2] - There is a focus on upgrading traditional industries and developing new productive forces, with an emphasis on strategic emerging industries such as artificial intelligence, new materials, and biomanufacturing [2]

Core Viewpoint - Lignin valorization is crucial for achieving economically viable and sustainable lignocellulosic biorefineries, with a focus on overcoming the challenges posed by expensive cofactors and enzyme activity imbalance [1][3][14] Group 1: Lignin Valorization Challenges - The continuous demand for expensive cofactors like ATP, NADPH, and CoA significantly hinders the sustainable conversion of lignin into valuable products [1] - The production rates of valuable molecules derived from lignin, such as raspberry ketone (RK) and curcumin, are extremely low, highlighting the inefficiencies in current conversion processes [1][3] Group 2: iMECS Strategy Development - The iMECS (in vitro multi-enzyme coordinated expression with cofactor self-circulation) strategy integrates cofactor regeneration and cell-free expression into the lignin upgrading process [3][4] - The iMECS platform demonstrated a 48-fold increase in overall catalytic efficiency without the addition of external cofactors, achieving a curcumin production rate of 0.175 g/L/h and a molar yield of 95.31% [3][6] Group 3: Multi-Enzyme Optimization - The study optimized the production of curcumin by establishing a biocatalytic module and introducing an in situ multi-cofactor recovery module, resulting in a curcumin yield of 126.4 mg/L [5][6] - The iMECS system achieved a curcumin production rate that was over 1455% higher than traditional whole-cell bioconversion methods [6] Group 4: Application to Vanillin Synthesis - The iMECS system was further evaluated for the conversion of ferulic acid to vanillin, achieving a vanillin yield of 94.4 mg/L with a 67% reduction in ATP demand [7][8] - The system's efficiency was enhanced by employing a temperature-guided biocatalytic process, which maintained enzyme activity while inactivating undesirable endogenous enzymes [9] Group 5: RK Biosynthesis - The iMECS strategy was applied to the more complex pathway of converting p-coumaric acid (pCA) to RK, achieving a production rate of 0.15 g/L/h and a conversion rate of 91.56% [10][13] - The integration of upstream and downstream modules within the iMECS system demonstrated significant potential for synthesizing more complex products from lignin-derived substrates [12][13] Group 6: Environmental and Economic Implications - The iMECS strategy promotes the use of lignin-rich agricultural waste as a feedstock, decoupling biomanufacturing from sugar prices and reducing greenhouse gas emissions compared to traditional petroleum-based synthesis [14]

精英计划-人才需求 | 天津工生所 中国科学院天津工业生物技术研究所是由中国科学院与天津市人民政府共建、整建制从事生物制造和 工业生物技术研究的国立科研机构，是我国工业生物领域的战略科技力量，肩负着创新生物产业关键 核心技术、发展生物制造重大颠覆性技术、支撑我国生物经济高质量可持续发展的历史使命，围 绕"以可再生碳资源替代化石资源、以清洁生物加工方式替代传统化学加工方式、以现代生物技术提 升产业水平"三大战略主题，重点开展"工业蛋白质科学与生物催化工程、合成生物学与微生物制造 工程、生物系统与生物工艺工程"三个领域方向的基础研究和应用基础研究。 招 聘部门 简介 01 邓子新大师工作室以活性天然产物的创新与绿色制造为目标，遵循"师从于自然、认知于自然，创新 于自然"的学术思路，运用合成生物学理念，聚焦交叉学科前沿，建立和完善天然药物精准发掘、结 构创新和优产新模式，实现微生物天然药物的高效生产。 团队由 徐敏研究员 与 侯安伟研究员 领衔，重点关注全新作用机制抗生素（糖肽抗生素）与萜类天 然产物的高效精准挖掘、生物合成机制与作用机制解析以及相关新分子的高效创制。 徐敏研究员主要从事微生物天然产物合成生物学以及 ...

Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. reported a significant increase in overseas revenue for 2024, driven primarily by growth in amino acid product sales and the introduction of new products [2][19]. Group 1: Overseas Revenue Performance - The company achieved overseas revenue of 1.032 billion yuan in 2024, accounting for 47.39% of total revenue, representing a year-on-year growth of 30.34% [2][19]. - The breakdown of overseas revenue shows that the main business revenue increased by 30.34% to 1.032 billion yuan, while other business revenue rose by 88.86% to 40.65 million yuan [2][5]. - The primary regions for overseas sales include Europe, America, and Asia, with varying gross profit margins due to differences in product structure [5][19]. Group 2: Audit Procedures and Findings - The annual audit firm conducted thorough procedures to verify the authenticity and accuracy of overseas revenue, including internal control evaluations and document checks [7][8]. - The audit confirmed that 74.73% of overseas revenue was verified through customer confirmations, indicating a high level of reliability in reported figures [9][21]. - The audit also matched overseas sales data with third-party data, such as export tax refund claims and foreign exchange management bureau data, revealing minimal discrepancies [11][12]. Group 3: Gross Margin Analysis - The company's overall gross margin for 2024 was reported at 24.92%, a decline of 15.60 percentage points from the previous year, primarily due to decreased margins in amino acid and vitamin products [21][22]. - The average selling prices for amino acids and vitamins fell significantly, with L-valine prices dropping by 17.89% and vitamin prices by 54.09% [23][24]. - The decline in gross margins is attributed to increased competition and market dynamics, with the company implementing measures to address these challenges [27][35]. Group 4: Future Outlook and Industry Trends - The demand for amino acids is expected to grow due to trends in precision nutrition and reduced reliance on traditional feed ingredients, which may positively impact future margins [27][29]. - The global market for biosynthetic vitamins is projected to grow significantly, indicating potential opportunities for the company as it expands its product offerings [29][30]. - The company is positioned to benefit from technological advancements in production processes, which may enhance cost efficiency and product competitiveness in the long term [31][32].

Core Viewpoint - The company reported a significant increase in overseas revenue for 2024, driven primarily by the growth in amino acid product sales and the introduction of new products, despite a decline in overall gross margin due to competitive pricing pressures in the market [2][18]. Group 1: Overseas Revenue Performance - The company achieved overseas revenue of 1.032 billion yuan in 2024, accounting for 47.39% of total revenue, representing a year-on-year growth of 30.34% [2][3]. - The main contributors to the overseas revenue growth were the amino acid series products, particularly L-valine, and the vitamin series products, which saw increased sales volumes [5][18]. - The company’s overseas sales were primarily concentrated in Europe (41.58%), the Americas (28.51%), and Asia & others (29.91%) [3][4]. Group 2: Gross Margin Analysis - The overall gross margin for the company in 2024 was reported at 24.92%, a decrease of 15.60 percentage points compared to the previous year [18]. - The gross margin for amino acid products was 30.00%, down 13.32 percentage points, while the vitamin products experienced a more significant decline [18][19]. - The decline in gross margin was attributed to lower average selling prices for key products such as L-valine and myo-inositol, which saw price drops of 17.89% and 54.09% respectively [19][20]. Group 3: Future Outlook and Industry Trends - The demand for amino acids is expected to continue growing due to trends in precision nutrition and the reduction of traditional feed ingredients like soybean meal [23][24]. - The global market for biosynthetic vitamins is projected to grow significantly, with a compound annual growth rate of 9.32% from 2024 to 2030, driven by advancements in synthetic biology [24]. - The company is positioned to benefit from its technological advantages in fermentation processes, which are more environmentally friendly and cost-effective compared to traditional methods [27][28].

Company Overview - Shandong Lukang Pharmaceutical Co., Ltd. was established on February 15, 1993, and is located at 88 Deyuan Road, Jining High-tech Zone, Shandong Province [18] - The company is listed on the Shanghai Stock Exchange with the stock code 600789, and its actual controller is the State-owned Assets Supervision and Administration Commission of the Shandong Provincial Government [18][19] - As of December 31, 2024, the total share capital of the company is 898,669,632 shares, with 100% being unrestricted shares [19] Issuance Plan - The company plans to issue shares to no more than 35 specific investors, including its controlling shareholder, Hualu Group, which intends to subscribe for 23.81% of the shares, amounting to no more than 64,201,417 shares [2][3][6] - The total amount of funds raised from this issuance is not expected to exceed 1.2 billion yuan (120,000 million yuan) [8] - The final issuance price will be determined based on the average trading price of the company's shares over the 20 trading days prior to the pricing benchmark date, with a minimum price set at 80% of this average [4][5] Industry Context - The global chemical pharmaceuticals market has shown stable growth, increasing from USD 924.8 billion in 2016 to USD 1,104.7 billion in 2022 [20] - The Chinese chemical pharmaceuticals market reached a scale of 801.2 billion yuan in 2016, experiencing fluctuations due to global public health events but is expected to recover starting in 2023 [20] - Chronic diseases, particularly cardiovascular diseases and diabetes, are key focus areas for the company, with significant patient populations and high medical costs associated with these conditions [21][20] Market Trends - The market for cardiovascular drugs in China has maintained growth from 2015 to 2019, with fluctuations from 2020 to 2022 due to public health events [21] - The market for type 2 diabetes treatment drugs in China has experienced volatility from 2018 to 2022 but is projected to grow steadily due to the introduction of innovative diabetes medications and increased awareness of comprehensive health management [21] - The antibiotic market in China has grown from 145 billion yuan in 2016 to 208 billion yuan in 2023, despite regulatory restrictions on antibiotic use [22]